Clinical Trial Update: Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing sirolimus with tacrolimus (Prograf) versus sirolimus with cyclosporine in high-risk renal transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Prograf (Tacrolimus)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Renal Allograft Recipients | Phase 3 | Status: COMPLETED